A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
about
Systemic delivery of oncolytic viruses: hopes and hurdlesNew viruses for cancer therapy: meeting clinical needsImmune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancersImproved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesPotential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsGoing viral: a review of replication-selective oncolytic adenovirusesReplication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesClinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Oncolytic virotherapy for pediatric malignancies: future prospectsTrial Watch-Oncolytic viruses and cancer therapyActivation of p53 by chemotherapeutic agents enhances reovirus oncolysisSickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In VivoA phase I trial of single-agent reolysin in patients with relapsed multiple myelomaPrime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyEnhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinomaAntiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.Glycan engagement dictates hydrocephalus induction by serotype 1 reovirus.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium reportStabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activationOncolytic virotherapy for pancreatic cancer.Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma modelsNaturally occurring reoviruses for human cancer therapy.Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesThe sweet spot: defining virus-sialic acid interactions.Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.
P2860
Q21284969-4406C21F-4E87-4A67-86E0-6DC61834F7E4Q24567699-542D5FB3-2BD9-4960-A550-CFE1A4C114AFQ24596171-7F7896AC-7A22-4997-9D47-4D5BA262D404Q24611483-4BC0810B-A144-46E3-97AE-A26E2C6EB2F4Q24612603-CF6AEE67-642C-4033-8DEC-7DD481017CA7Q24617027-24E3DDA6-4C36-4AB7-98E7-4B7A1C5F3011Q26750568-C5356123-D608-44A8-BC05-99279C4589C0Q26752807-A9D7A279-A711-4F0C-BF3F-9903BD5B288AQ26775033-B484C35D-26ED-4E9F-ABFC-97F8D31C4FD0Q26797520-55BA39FB-227F-4B91-9BFB-B9A93049EAA5Q26801501-A5883DD0-50CE-46B3-A6F2-73A7AD2E94FAQ26863779-A3AAFA27-7A24-4AC0-A346-5BC065C3DCC8Q27690634-2702831E-CB33-4AD8-93F5-502B3FB7744FQ28069358-02E4E548-ED16-4F9B-8E5D-90A45EB45A94Q28072347-BB2E4969-6F42-4A61-B057-E9AD17921A4AQ28485141-B37AAE75-CDE1-4A36-824F-A6E881BC5634Q28596621-F08D7E33-7C27-48A1-B6A0-EDBCAFF0F3D4Q33418048-9E0E0B97-D5BB-4C6B-A22A-22F250B079F0Q33551626-59AA7A9B-2248-49D0-9330-FDC6A789375DQ33731148-B42B2274-36E2-4E11-942E-AEF128404D7DQ33815701-B8A760CA-0899-4AC1-BAA3-83F1E12CA5DFQ33924515-0B6CD1F7-7FBF-4779-B756-8CC9FD55EE85Q34393001-2BA17AF7-ED4B-4FB9-93D2-3E868AC6FCE1Q34421151-0B2C8953-CD3D-4828-BA90-CCBD86A56602Q34460916-47697C57-78A0-47BB-B026-8BAFC09E1C12Q35172332-7E2DBD74-A19A-41CA-84D9-EA0B1EE9C22CQ35224368-C75A8BEE-A7E5-4761-9BD3-869168223DBBQ35262964-827027ED-7AE7-44CE-9CDE-7E67A7126EE9Q35590996-7D574428-B06E-4C09-A2DE-E2E3D4B459D5Q35596563-570F3FC8-08FC-45F6-8FAB-8FC4A1ADFAF2Q35812675-5B6AE734-D69C-44EC-AE27-F89EF0E3FA9EQ36076671-7772C2C8-15B3-47B0-91E6-8B2F30EA1BBAQ36078485-EB1C1901-8552-4DBD-B186-A3BFB736679CQ36140704-1D2B8E5B-36E9-4B39-804A-72183415AC4BQ36298608-F3295D02-35CE-4DA7-9111-7F7D8046FBC6Q36574519-AA230DA9-C4C3-42A8-9560-84528E0FB28CQ36582819-B3575846-0E81-4B59-90C5-E1A093EE3B32Q36685206-9F330102-C0AC-485A-AD1D-8D964E13E5A9Q36766032-C09BA032-01F6-4053-9896-91AD3F8C0FF8Q36766052-C35EC24A-6001-49F9-9181-DD778FA48B6F
P2860
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A phase I study of intravenous ...... patients with advanced cancer.
@en
A phase I study of intravenous ...... patients with advanced cancer.
@en-gb
type
label
A phase I study of intravenous ...... patients with advanced cancer.
@en
A phase I study of intravenous ...... patients with advanced cancer.
@en-gb
prefLabel
A phase I study of intravenous ...... patients with advanced cancer.
@en
A phase I study of intravenous ...... patients with advanced cancer.
@en-gb
P2093
P1476
A phase I study of intravenous ...... patients with advanced cancer.
@en
P2093
Christine L White
Hardev S Pandha
Johann S DeBono
Katie Twigger
Kevin J Harrington
Laura Vidal
Matt Coffey
Richard G Vile
Timothy A Yap
P304
P356
10.1158/1078-0432.CCR-08-0524
P407
P50
P577
2008-11-01T00:00:00Z